DARMKANKER.

Informatie over actuele ontwikkelingen in zowel reguliere als alternatieve en/of aanvullende behandelingen en middelen bij darmkankersoorten in alle stadia. We hebben in principe alle artikelen en informatie op alfabetische volgorde gezet, scroll in linkerkolom in alfabetische lijst.

Ervaringen van kankerpatienten met complementaire aanpak zijn te vinden onder ervaringsverhalen en er zijn ook een aantal video's van ervaringen van kankerpatienten te zien. Aan te klikken via videoknop linksbovenaan . Of ga naar de website van het SNFK waar voorlichtingsfilmpjes zijn te zien over complementaire aanpak bij kanker.

Diagnose van darmkanker: M2-PK is een enzym die voorkomt in de faeces - ontlasting en kan de ontwikkeling/aanwezigheid van darmkanker voorspellen

14 september 2004: Bron: British Journal of Cancer (2004) 91, 980-984. doi:10.1038/sj.bjc.6602033 Published online 13 July 2004

Onderzoekers hebben ontdekt dat in de faeces - ontlasting - van mensen met darmkanker een bepaald stofje -enzym met de naam M2-PK oververtegenwoordigd is in de faeces in vergelijking met mensen die geen darmkanker hebben. Deze eenvoudig uit te voeren test zou vroegtijdig kunnen vaststellen of iemand darmkanker ontwikkelt ja of nee. Hieronder het abstract zoals gepubliceerd in the British Journal of Cancer.

Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer

P D Hardt1, S Mazurek2, M Toepler3, P Schlierbach3, R G Bretzel1, E Eigenbrodt2, and H U Kloer1 1Third Medical Department and Policlinic, Giessen University Hospital, Justus-Liebig-University of Giessen, Rodthohl 6, Giessen 35392, Germany
2Institute of Biochemistry and Endocrinology, Veterinary Faculty, University of Giessen, Frankfurter Strasse 100, Giessen 35392, Germany 3Medical Department and Surgical Department of the Asklepios Clinic, Goethestrasse 4, Lich 35423, Germany
Correspondence to: Dr PD Hardt, E-mail: Philip.D.Hardt@innere.med.uni-giessen.de

This work is dedicated to the memory of Professor Erich Eigenbrodt who died in June 2004. His fundamental research in tumour metabolism resulted in the development of tumour M2-PK tests and their introduction for clinical applications.

Received 30 December 2003; revised 20 May 2004; accepted 7 June 2004; published online 13 July 2004

Proliferating cells, especially tumour cells, express a special isoenzyme of pyruvate kinase, termed M2-PK, which can occur in a tetrameric form with a high affinity to its substrate, phosphoenolpyruvate (PEP), and in a dimeric form with a low PEP affinity. In tumour cells, the dimeric form is usually predominant and is therefore termed Tumour M2-PK. The levels of Tumour M2-PK within tumours and in EDTA-plasma correlate with staging and the ability of the tumour cells to metastasise. Since most colorectal tumours grow intraluminally, it appeared interesting to determine whether Tumour M2-PK is detectable in the faeces of tumour patients. Stool samples were tested by ELISA from controls without colorectal cancer and colorectal cancer patients. Whereas Tumour M2-PK levels were low in the control group (mean value±s.e.m.: 3.3±0.4, n=144), they were high in the case of colorectal cancer (56.1±15.3, n=60). At a cutoff value of 4 U ml-1, the sensitivity was 73%. TNM and Dukes' classification of the tumours revealed a strong correlation between faecal Tumour M2-PK levels and staging. The determination of Tumour M2-PK in faeces provides a new promising screening tool for colorectal tumours.